Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics
Abstract Background Oral cancer therapy-related cardiovascular (CV) toxicity has a wide variety of presentations including arrhythmia, cardiomyopathy, and myocardial infarction, but clinical evidence related to its management is limited. The purpose of this IRB-approved, single-center, retrospective...
Main Authors: | Karen Abboud, Godsfavour Umoru, Barry Trachtenberg, Veronica Ajewole |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-04-01
|
Series: | Cardio-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40959-024-00221-5 |
Similar Items
-
Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology
by: Samaneh Zandifar, et al.
Published: (2024-01-01) -
Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology
by: Zehua Liang, et al.
Published: (2022-09-01) -
Risk Stratification and Management of Arterial Hypertension and Cardiovascular Adverse Events Related to Cancer Treatments: An Oncology Network from Piedmont and Aosta Valley (North-Western Italy) Consensus Document
by: Giulia Mingrone, et al.
Published: (2021-01-01) -
Current State of Pediatric Cardio-Oncology: A Review
by: Molly Brickler, et al.
Published: (2022-01-01) -
Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease
by: Joseph Pierre Aboumsallem, et al.
Published: (2020-01-01)